DDInter1266 DDInter53
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Warfarin (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib